PharMerica and its parent company, BrightSpring Health Services, Inc., disclosed it learned of suspicious activity on its computer network on March 14 and an internal investigation determined the unknown third party accessed computer systems from March 12-13 and may have obtained personal…
Source: www.healthcareitnews.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
